Iq-ai Share Discussion Threads

[cantabile] 06/1/2021 12:38

@Volsung

Sorry 😕

[cantabile] 06/1/2021 12:36

@Bobby

Nothing 'random' about it, in fact it's quite SPECIFIC as it's an image of Festario ..

[bobby.ifa] 06/1/2021 12:32

This is not a playground, please keep it relevant to Company specific items, not random stalking images.

[chesty1] 06/1/2021 12:01

And you wonder why half of advfn loves to post pictures of you! Just pointing out you cannot sell currently if you wanna prove me wrong go for it!

Flashed up you could sell 10 mins ago @ just over 11p & someone took it...now cannot sell again! Woof Woof!

[festario] 06/1/2021 11:47

Probably ramping... as he missed out on this delicious, oversold recovery.

[festario] 06/1/2021 11:44

Is that fool Chesty back ramping, or de-ramping?You can never tell with liars like him. Hence why he's on ignore user.

[chesty1] 06/1/2021 11:35

Just tried dummy trades for IQAI

Can buy @11.2499p but cannot sell a bean! hhhhmmmm dump due? who knows....

[master rsi] 06/1/2021 11:27

Some will regret doing so chart say catch up is due

[festario] 06/1/2021 11:21

Let a few profit takers out at 11.5p

[master rsi] 06/1/2021 11:15

40K on the phone done the trick...

11:12:18 11.25p 40,000 £4,500

already 11 v 12p

[master rsi] 06/1/2021 11:13

3 at bid 1 at offer but by phone
no wonder no trades done for the last 5 minutes

bid level 2
10:44 JBER 75,000 10.5
10:54 PEEL 75,000 10.5
10:49 SING 75,000 10.5
09:49 SCAP 75,000 10.25
10:47 WINS 100,000 10
07:49 CFEP 75,000 9.5
07:58 STFL 75,000 9.5

OFFER side
11.25 75,000 STFL 07:58
11.5 75,000 CFEP 07:49
11.5 75,000 SING 10:49
12 75,000 JBER 10:44
12 75,000 SCAP 09:49
12 100,000 WINS 10:47
12.5 75,000 PEEL 10:54

[master rsi] 06/1/2021 11:11

There is places where are saying not able to buy on platform
call the broker

[festario] 06/1/2021 11:05

Bidding above mid now, at 10.93p Squeeze is back on, due to the small free float.

[howdlep] 06/1/2021 10:53

Three excellent posts by VP007 over on LSE. I have combined them here so I can provide a link from Twitter as well:-

Incase any investors missed this, I think 2021 will be the year IQAI capitalise on the sevens fold growth of the Telehealth market in the US.

Source: hxxps://www.healtheuropa.eu/explosion-in-telehealth-market-due-to-covid-19/100127/

From the 2020 Half Year Report:

Teleradiology and Expanding Distribution

Since the inception of IQ-AI's subsidiary, Imaging Biometrics™, LLC ("IB, the foundational architectural design strategy of the products has been to build them as platform independent plugins. Steadfast in this approach, IB has successfully translated advanced technologies into portable clinical solutions that readily extend the base functionality of established workstations, medical viewing stations, PACS, and servers. A logical application of the platform-independent design of IB's products is in telehealth. With the onset of Covid-19, healthcare providers had to find new ways to stay connected with patients and administer care. The field of telehealth is exploding and is, for all intents and purposes, and untapped market. During the review period, three licenses of IB Neuro were deployed specifically in teleradiology application. While IB's current products readily lend themselves as natural value-add extensions to established teleradiology platforms, the Company is exploring more direct applications and platforms in the rapidly emerging telehealth space.

Watch this space as this could lead to exponential growth for the company...

Let’s recap why the share price is completely undervalued.

The company has the following products:

On the market:

IB Clinic 2.0 - FDA, CE Approved

IB Clinic consists of perfusion weighted imaging and permeability computation modules IB Neuro and IB DCE, diffusion weighted imaging analysis module IB Diffusion, image co-registration and manipulation module IB Delta Suite, and IB Rad Tech, which streamlines and automates customizable workflows.

StoneChecker 2.0 - Approved for US, Europe and South Korea

Recently upgraded based on potential client feedback and AI workflows to be included in the next upgrade early this year.

Liver Surface Nodularity (LSN) Software - FDA and CE approved

LSN's proprietary algorithms process CT images of a patient's liver to assess the nodules along the liver surface. This virtual biopsy offers a low cost, low-risk, non-invasive alternative that may aid in the staging of CLD and has the potential to become the standard of care for a significant global market.

IB Stroke - FDA and CE approved

A key differentiator for IB Stroke resides in the core Imaging Biometrics' ("IB") algorithms that will be used to generate output commonly used for stroke assessment. Specifically, the ability to automatically quantify blood volume and other perfusion parameters is unique to IB. The initial launch of IB Stroke will be within an IB Rad Tech workflow, which is already installed at leading neurological centres.

In the pipeline:

IB CAD

IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.

IB Trax - in partnership with the Mayo Clinic

This application will leverage the proven ability of quantitative Delta T1 maps, among other technologies, and focus on an improved workflow for evaluating both brain metastases and primary brain cancer across time. For almost a decade, IB's medical advisors and end-users of IB Neuro have considered that the manually intensive way currently used to longitudinally assess brain lesions is cumbersome and prone to error. IB Trax represents an efficient and streamlined platform that will address a significant and immediate need for routine clinical use.

Gad Free Imaging

Another disruptive technology under development by the Company is the ability to generate a contrast-free MRl image that is equivalent to one acquired with contrast. AI networks have been created and are being trained using only anatomical and functional images free of any exogenous contrast material. The ability to completely eliminate the administration of contrast material has significant benefits on multiple levels. Along with substantial financial savings that can be realised, the on-going concerns about the long-term effects of gadolinium deposition throughout the body can be avoided.

Telehealth

Since the inception of IQ-AI's subsidiary, Imaging Biometrics™, LLC ("IB, the foundational architectural design strategy of the products has been to build them as platform independent plugins. Steadfast in this approach, IB has successfully translated advanced technologies into portable clinical solutions that readily extend the base functionality of established workstations, medical viewing stations, PACS, and servers. A logical application of the platform-independent design of IB's products is in telehealth. With the onset of Covid-19, healthcare providers had to find new ways to stay connected with patients and administer care. The field of telehealth is exploding and is, for all intents and purposes, and untapped market. During the review period, three licenses of IB Neuro were deployed specifically in teleradiology application. While IB's current products readily lend themselves as natural value-add extensions to established teleradiology platforms, the Company is exploring more direct applications and platforms in the rapidly emerging telehealth space.

Distribution / Partnerships

Eureka Clinical AI, QMENTA, Blackford Analysis, Medimsight, CorTechs Labs, Arterys, aycan Medical Systems, Pixmeo

Grants

IB received a five-year, $2.57 million, NIH grant award in collaboration with The Barrow Neurological Institute (BNI), the Mayo Clinic in Arizona, and the Medical College of Wisconsin (MCW).

This award follows the previously announced five-year, $2.8 million award IB received in late 2019. Together, these grants provide long-term funding to execute the respective goals and, at current staffing levels, subsidise over 60% of IB's development costs. Additional grants have been submitted to the NIH.

All of their products are targeted at $bn markets...

...so taking into consideration all of the above...it’s hard not to believe that the share price will be multiples of where it is today.

[hernando2] 06/1/2021 10:25

Well i made a decent whack on BHR after selling out here and RMS..so back in here for TB’s next expression of interest!!

[festario] 06/1/2021 00:52

Ha ha... Dean Haigh, convicted stalker, Filtered.

[code selfish] 06/1/2021 00:10

Here we go again with the completely unfounded accusations, earlier he claimed I had 'Swastika Tattoos' (and 'such like') I've been on the 'dole all my life' (PIP since 2014) and now I'm a former prisoner (the only time I've been in prison is when my old company stripped all the asbestos out of Armley)

Might be a good idea to take the filter off on Nobby's thread Pete (if indeed it's ever been on) you, your wife, Golfy, the Castro's, Peter Kearney and a load of other fat ugly b*stards from your darts club have all been ridiculed tonight., laughs all round.

And before you accuse all the new posters of being me, have a look at their post histories.

[clancy eccles] 05/1/2021 23:43

Two Questions Fest:

1. What was in the envelope ?

2. Why don't you have a neck ?

[festario] 05/1/2021 23:27

Yes Sloppy Joe.Haigh is, and always has been, a dole dossing, scrounging low life filth.

[clancy eccles] 05/1/2021 22:03

The somewhat scary old chap above is Golfy Owen, a one time neighbour and still good friend of Fest, not a nice man all in all, seems to think he can get away with being rude, arrogant and aggressive merely because he is very old (almost 90)

So Fest is happy to have this unpleasant old duffer as a 'friend' but he ridicules Haigh for being 'almost 60'

Very odd 🤔